Education
About Us
Working with TipRanks
Follow Us
Calcimedica, Inc. (CALC)
NASDAQ:CALC
CALC Stock Chart & Stats
$4.19
<$0.01(0.05%)
At close: 4:00 PM EST
$4.19
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$1.42 - $4.82
Previous CloseN/A
Volume2.29K
Average Volume (3M)71.94K
Market Cap
$75.22M
Enterprise Value$41.19M
Total Cash (Recent Filing)$14.08M
Total Debt (Recent Filing)$8.90M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Mar 26, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding14,409,431
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.76
Price to Sales (P/S)0.00
P/FCF Ratio-1.88
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.94K
Enterprise Value/Ebitda-1.88
Forecast
1Y Price Target
$20.00Price Target Upside377.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAuxora shows significant clinical efficacy with a 62.7% relative reduction in mortality for patients compared to placebo.
Clinical Trial ProgressCalciMedica is making progress with its lead clinical candidate, Auxora, through continued advancement in clinical trials.
Operational FundingThe company has secured enough cash to sustain operations into mid-2026, providing stability for ongoing projects.
Regulatory EngagementProductive initial meetings with the FDA regarding Auxora's Phase 3 study design signal positive regulatory engagement.
Bears Say
Financial PerformanceCalciMedica announced a financial result with EPS of ($0.36), which was below both the estimate and consensus expectations.
Funding RequirementsInitiation of the Phase 3 study in acute pancreatitis by year-end 2025 is contingent upon securing additional funding.
CalciMedica News
CALC FAQ
What was Calcimedica, Inc.’s price range in the past 12 months?
Calcimedica, Inc. lowest stock price was $1.42 and its highest was $4.82 in the past 12 months.
What is Calcimedica, Inc.’s market cap?
Calcimedica, Inc.’s market cap is $75.22M.
When is Calcimedica, Inc.’s upcoming earnings report date?
Calcimedica, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 97 days.
How were Calcimedica, Inc.’s earnings last quarter?
Calcimedica, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.108.
Is Calcimedica, Inc. overvalued?
According to Wall Street analysts Calcimedica, Inc.’s price is currently Undervalued.
Does Calcimedica, Inc. pay dividends?
Calcimedica, Inc. does not currently pay dividends.
What is Calcimedica, Inc.’s EPS estimate?
Calcimedica, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Calcimedica, Inc. have?
Calcimedica, Inc. has 14,409,431 shares outstanding.
What happened to Calcimedica, Inc.’s price movement after its last earnings report?
Calcimedica, Inc. reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went up 4.05%.
Which hedge fund is a major shareholder of Calcimedica, Inc.?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CalciMedica Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (377.33% Upside)
$20.00 (377.33% Upside)
Blogger Sentiment
Bullish
CALC Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $78.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.15%
12-Months-Change
Fundamentals
Return on Equity
-526.36%
Trailing 12-Months
Asset Growth
-8.01%
Trailing 12-Months
Company Description
Calcimedica, Inc.
CalciMedica (CALC) is a biotechnology company focused on the development of therapies to treat inflammatory and autoimmune diseases. The company specializes in targeting calcium release-activated calcium (CRAC) channels, which play a crucial role in the activation of immune cells. CalciMedica's lead product candidate is Auxora, a CRAC channel inhibitor designed to treat severe inflammatory diseases such as acute pancreatitis and COVID-19 pneumonia.
CALC Stock 12 Month Forecast
Average Price Target
$20.00
▲(377.33% Upside)
Technical Analysis
Ownership Overview
39.32% Insiders
2.89% Mutual Funds
19.48% Other Institutional Investors
35.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---